Navigation Links
Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians

Support for Grassley-Kohl Bill Newest Addition to Lilly's 'Transparency


INDIANAPOLIS, May 13 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company (NYSE: LLY) announced its support of the newly revised Physicians Payments Sunshine Act, sponsored by United States Senators Charles Grassley (R-Iowa) and Herbert Kohl (D-Wisconsin). The bipartisan bill would establish a national registry of payments to physicians by medical device, medical supply and pharmaceutical companies. Lilly is the first pharmaceutical research company to back such federal legislation, which is similar to various laws in place in several states.

"Lilly welcomes greater transparency in the health care system and believes this legislation represents an important step in building public trust and confidence in the relationships between the pharmaceutical and device industries and physicians," said John C. Lechleiter, Ph.D., president and chief executive officer of Eli Lilly and Company. "Lilly intends to continue to build upon its leadership position in transparency. In addition to our publicly available clinical trial and educational grant registries, we continue to look at other ways to open up our business to the public. This will help provide the assurance that Lilly runs its business consistent not only with our principles, but with the principles that a healthcare provider or patient should expect from a pharmaceutical company."

Noting the benefits of the federal standard for reporting payments to doctors, Lechleiter added, "A key strength of the Grassley-Kohl bill is that it would create a uniform national standard for reporting physician payments. This helps patients, businesses and doctors alike by setting expectations and creating a more efficient system for gathering, reporting and understanding such data."

"Lilly is proud of the longstanding relationships we have with physicians," said Jack Harris, M.D., Lilly's vice president, U.S. Medical Division. "Physicians perform valuable services for the biopharmaceutical industry, such as enrolling and caring for patients in clinical trials. They also give lectures to other medical professionals to educate them about new treatment options. For these services they are compensated at market rates. Moreover, these services help to advance the science related to medicines and are important to both current and future patients who rely on pharmaceuticals as part of their therapy."

Support for the Grassley-Kohl bill is the newest addition to what Lilly terms its "transparency agenda." In 2004, Lilly became the first company to voluntarily make public its clinical trials and its clinical trials data; that information can be found at And last year Lilly added another first by publicly reporting all of its educational grants and charitable contributions and, each quarter, posting the data online at

As a leader on this issue, Senator Grassley has recognized Lilly's efforts. In February 2008, Sen. Grassley sent 15 companies a letter about transparency and called out Lilly's leadership. That letter read in part: "I'm asking other pharmaceutical organizations to follow Lilly's lead and show the public there's nothing to hide."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at

(Logo: )


SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
2. Lilly CEO Urges Policy Prescriptions to Help Ensure Public and Private Biotech Investments Generate Dividends and U.S. Job Growth
3. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
4. Lilly Reports Solid First-Quarter Results
5. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
6. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
7. Lilly Announces Termination of AIR Insulin Program
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
10. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
11. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
(Date:11/24/2015)... ... 24, 2015 , ... This fall, global software solutions leader SAP and AdVenture ... develop and pitch their BIG ideas to improve health and wellness in their schools. ... to win the title of SAP's Teen Innovator, an all-expenses paid trip to Super ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... , October 23, 2015 ... announce a mobile plug and play integration of physiological ... tasks SensoMotoric Instruments (SMI) present a ... solutions for eye tracking and physiological data registration. It ... SMI Eye Tracking Glasses 2w and physiological signals ...
Breaking Biology News(10 mins):